Literature DB >> 12709349

In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria.

Barbara A Brown-Elliott1, Christopher J Crist, Linda B Mann, Rebecca W Wilson, Richard J Wallace.   

Abstract

MICs of linezolid in broth microdilutions were tested against 341 slowly growing nontuberculous mycobacteria (NTM) belonging to 15 species. The proposed linezolid susceptibility MICs for all Mycobacterium marinum, Mycobacterium szulgai, Mycobacterium kansasii, Mycobacterium malmoense, and Mycobacterium xenopi isolates and for 90% of Mycobacterium gordonae and Mycobacterium triplex isolates were </=8 micro g/ml. Linezolid has excellent therapeutic potential against most species of NTM.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12709349      PMCID： PMC153345          DOI： 10.1128/AAC.47.5.1736-1738.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Mycobacterium wolinskyi sp. nov. and Mycobacterium goodii sp. nov., two new rapidly growing species related to Mycobacterium smegmatis and associated with human wound infections: a cooperative study from the International Working Group on Mycobacterial Taxonomy.

Authors:  B A Brown; B Springer; V A Steingrube; R W Wilson; G E Pfyffer; M J Garcia; M C Menendez; B Rodriguez-Salgado; K C Jost; S H Chiu; G O Onyi; E C Böttger; R J Wallace
Journal:  Int J Syst Bacteriol       Date:  1999-10

2.  Successful treatment of disseminated Mycobacterium chelonae infection with linezolid.

Authors:  B A Brown-Elliott; R J Wallace; R Blinkhorn; C J Crist; L B Mann
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

3.  Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis.

Authors:  A Telenti; F Marchesi; M Balz; F Bally; E C Böttger; T Bodmer
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

4.  In vitro activities of linezolid against multiple Nocardia species.

Authors:  B A Brown-Elliott; S C Ward; C J Crist; L B Mann; R W Wilson; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Activities of linezolid against rapidly growing mycobacteria.

Authors:  R J Wallace; B A Brown-Elliott; S C Ward; C J Crist; L B Mann; R W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  Clinical experience with linezolid for the treatment of nocardia infection.

Authors:  Edina H Moylett; Susan E Pacheco; Barbara A Brown-Elliott; Tracy R Perry; E Stephen Buescher; Mary C Birmingham; Jerome J Schentag; Joseph F Gimbel; Aaron Apodaca; Margot A Schwartz; Robert M Rakita; Richard J Wallace
Journal:  Clin Infect Dis       Date:  2003-01-13       Impact factor: 9.079

7.  PCR amplification and restriction endonuclease analysis of a 65-kilodalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria.

Authors:  V A Steingrube; J L Gibson; B A Brown; Y Zhang; R W Wilson; M Rajagopalan; R J Wallace
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

8.  Evaluation of nonradioactive DNA probes for identification of mycobacteria.

Authors:  L Lebrun; F Espinasse; J D Poveda; V Vincent-Levy-Frebault
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

9.  In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.

Authors:  Luis Alcalá; María Jesús Ruiz-Serrano; Cristina Pérez-Fernández Turégano; Darío García De Viedma; Marisol Díaz-Infantes; Mercedes Marín-Arriaza; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191
  9 in total
  16 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.

Authors:  Baohong Ji; Sébastien Lefrançois; Jerome Robert; Aurélie Chauffour; Chantal Truffot; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Mycobacterium paraffinicum causing symptomatic pulmonary infection.

Authors:  Austin W Chan; Sarah Kabbani; Gerald Staton; Colleen S Kraft
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

4.  In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.

Authors:  Lucio Vera-Cabrera; Barbara A Brown-Elliott; Richard J Wallace; Jorge Ocampo-Candiani; Oliverio Welsh; Sung Hak Choi; Carmen A Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

5.  Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.

Authors:  Zofia Bakuła; Magdalena Modrzejewska; Lian Pennings; Małgorzata Proboszcz; Aleksandra Safianowska; Jacek Bielecki; Jakko van Ingen; Tomasz Jagielski
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

6.  In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

7.  Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.

Authors:  Fernando Alcaide; Laura Calatayud; Miguel Santín; Rogelio Martín
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 8.  Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis.

Authors:  Janice M Leung; Kenneth N Olivier
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

9.  First Canadian Reports of Cervical Adenitis Due to Mycobacterium Malmoense and a 10-year Review of Nontuberculous Mycobacterial Adenitis.

Authors:  Chris McCrossin; Tim Mailman
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-03       Impact factor: 2.471

Review 10.  NTM drug discovery: status, gaps and the way forward.

Authors:  Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal:  Drug Discov Today       Date:  2018-04-07       Impact factor: 7.851
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.